CORALreef OUTCOMES
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
- Stage
- followup
- Medicine
- enlicitide (oraal PCSK9-i)
- Population
- ASCVD
- Phase
- III
- First Patient In
- 10 June 2024
- Last Patient In
- 24 July 2025
- Last Patient Last Visit
- 1 November 2029
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Study Director
dr. L. Kleijn
Cardioloog
Office Contact
